- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01189864
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
October 10, 2018 updated by: Cxlusa
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin.
The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication.
The data generated by this study will not be submitted to the FDA to support commercialization of these riboflavin drops.
Study Overview
Status
Terminated
Conditions
Study Type
Observational
Enrollment (Actual)
3493
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Schwartz Laser Eye Center
-
-
California
-
Laguna Hills, California, United States
- Harvard Eye Associates
-
San Diego, California, United States
- Clear View Eye & Laser Medical Center
-
San Francisco, California, United States
-
West Hills, California, United States
- Davidorf Eye Group
-
-
Colorado
-
Littleton, Colorado, United States
- Corneal Consultants of Colorado, P.C
-
-
Florida
-
Miami, Florida, United States, 33176
- The Center for Excellence in Eye Care
-
-
Illinois
-
Hoffman Estates, Illinois, United States, 60169
- Chicago Cornea Consultants, LTD
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- TLC Laser Eye Center
-
-
Massachusetts
-
Waltham, Massachusetts, United States
- Talamo Laser Eye Center
-
-
Missouri
-
Saint Louis, Missouri, United States
- Ophthalomology Associates
-
-
New York
-
Wantagh, New York, United States, 11793
- South Shore Eye Care LLP
-
-
Ohio
-
Brecksville, Ohio, United States, 44141
- Cleveland Eye Clinic
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- TLC Laser Eye Center
-
-
Washington
-
Seattle, Washington, United States
- Northwest Eye Surgeons
-
Spokane Valley, Washington, United States
- Empire Eye Physicians
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Primary care clinic.
Description
Inclusion Criteria:
- 12 years of age or older
- Diagnosis of keratoconus, FFKC, post-LASIK ectasia, or pellucid marginal degeneration or forme fruste pellucid marginal degeneration (FFPMD).
- Diagnosis of FFKC
- History of Radial Keratotomy with fluctuating vision
- Ability to provide written informed consent
- Likely to complete all study visits
- Minimum corneal thickness of at least 300 Measured by ultrasound or Pentacam
- At least 6 months since last corneal surgery (Intacs/PRK/LASIK/Epi-LASIK/LASEK)
Exclusion Criteria:
- Severe corneal scarring that markedly affects vision
- Contraindications to any study medications or their components
- Pregnancy or breast feeding
- Active Herpes Corneal Disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Nonsteroidal (Acular, Voltaren Xibrom, etc)
|
Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
|
Steroid (FML, Pred Forte, Flarex, etc.)
|
Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
|
Ciprofloxicin or Vigamox or other.
|
Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Hovanesian, MD, Harvard Eye Associates
- Principal Investigator: Jodi Luchs, MD, South Shore Eye Care LLP
- Principal Investigator: Shamik Bafna, MD, Cleveland Eye Clinic
- Principal Investigator: Jay Schwartz, MD, Schwartz Laser Eye Center
- Principal Investigator: Jonathan Davidorf, MD, Davidorf Eye Group
- Principal Investigator: Daniel Goodman, MD, Goodman Eye Center
- Principal Investigator: Jonathan Talamo, MD, Talamo Laser Eye Center
- Principal Investigator: Sandy Feldman, MD, Clear View Eye & Laser Medical Center
- Principal Investigator: Gregg Berdy, MD, Ophthalomology Associates
- Principal Investigator: Lance Forstot, Corneal Consultants of Colorado, P.C
- Principal Investigator: Mark Kontos, MD, Empire Eye Physicians
- Principal Investigator: Audrey Rostov, MD, Northwest Eye Surgeons
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2010
Primary Completion (Actual)
February 3, 2017
Study Completion (Actual)
February 3, 2017
Study Registration Dates
First Submitted
July 20, 2010
First Submitted That Met QC Criteria
August 25, 2010
First Posted (Estimate)
August 27, 2010
Study Record Updates
Last Update Posted (Actual)
October 12, 2018
Last Update Submitted That Met QC Criteria
October 10, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Corneal Diseases
- Keratoconus
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Diclofenac
Other Study ID Numbers
- CXL (12 & older)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratoconus
-
The Cleveland ClinicUniversity of MarylandEnrolling by invitationKeratoconus | Keratoconus, Unstable | Keratoconus, StableUnited States
-
Eye Hospital Pristina KosovoActive, not recruitingKeratoconus | Keratoconus of Right Eye | Keratoconus, Unstable, Right EyeKosovo
-
Tianjin Eye HospitalRecruitingScansys, Pentacam, Keratoconus, Subclinical KeratoconusChina
-
Tianjin Eye HospitalActive, not recruitingScansys, Pentacam, Corvis ST, Keratoconus, Subclinical KeratoconusChina
-
Heba Allah Nashaat MohamedAssiut UniversityRecruitingKeratoconus, CollagenEgypt
-
Kent Wellish MDNot yet recruitingKeratoconus, Unstable
-
Kasr El Aini HospitalUnknownProgressive KeratoconusEgypt
-
Centre Hospitalier Régional Metz-ThionvilleCompletedProgressive Keratoconus
-
Glaukos CorporationCompletedProgressive KeratoconusUnited States
-
Tianjin Eye HospitalCompletedKeratoconus, StableChina
Clinical Trials on Ciprofloxicin or Vigamox or other.
-
Eunice Kennedy Shriver National Institute of Child...CompletedPelvic Organ Prolapse | Stress Urinary IncontinenceUnited States
-
University of SouthamptonMicrosoft Research; Royal Academy of EngineeringCompleted(Focus) Posture Effect on Cognitive PerformanceUnited Kingdom
-
Tianjin Anding HospitalRecruitingHealthy | Anxiety DisorderChina
-
Hospital Ambroise Paré ParisCompletedLumbar RadiculopathyFrance
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
University of PadovaUniversity Medical Center Groningen; Azienda Ospedaliera Universitaria Integrata... and other collaboratorsRecruitingArrhythmia | Heart Defects, Congenital | Congenital Heart Disease | Sudden Cardiac Death | Surgical Procedure, Unspecified | Diagnosis | Adult Children | Coronary Artery AnomalyItaly, Switzerland
-
Sahlgrenska University Hospital, SwedenRecruiting
-
Samjin Pharmaceutical Co., Ltd.Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Kangpu Biopharmaceuticals, Ltd.CompletedCastration-Resistant Prostate CancerUnited States